Mymcpl is a Missouri-based nonprofit organization that provides notary, remote printing, and passport services for individuals.
With a global footprint spanning Europe, North and South America, Asia, and Africa, Sodecia operates business units that partner with the worlds leading automakers to develop innovative products and services. We specialize in stamping and welding, producing high-quality automotive components. Our technology centers in Europe provide comprehensive collaborative engineering services, delivering solutions that add value through advanced technologies, sustainability, agility, simplicity, and customer satisfaction. Sustainability is at the heart of our operations. We are committed to reducing our environmental impact through various initiatives, including the implementation of cutting-edge technologies and sustainable practices. Our dedication to sustainability ensures that we are not only meeting the needs of today but also preserving resources for future generations. At Sodecia, we believe in continuous improvement and innovation. Our global team is dedicated to enhancing the quality of life through the development of solutions for the automotive sector. Together, we are driving forward to create a safer, more efficient, and sustainable future. Explore more about our mission and values on our website.
Delrin® is a highly adaptable acetal homopolymer resin that bridges the performance gap between plastics and metals and offers unique properties. Manufacturers count on Delrin® for high load mechanical applications and precision parts, where strength, stiffness, stability, and reliability are important. Applications range from gears, safety restraint components, door system, and conveyor systems components to medical delivery devices, ski bindings, zip fasteners and many others across a wide range of products and industries
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.